Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 500

1.

Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.

Lindsey JC, Malee KM, Brouwers P, Hughes MD; PACTG 219C Study Team.

Pediatrics. 2007 Mar;119(3):e681-93. Epub 2007 Feb 12.

PMID:
17296781
2.

A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy.

Alimenti A, Forbes JC, Oberlander TF, Money DM, Grunau RE, Papsdorf MP, Maan E, Cole LJ, Burdge DR.

Pediatrics. 2006 Oct;118(4):e1139-45. Epub 2006 Aug 28.

PMID:
16940166
3.

Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.

Gaughan DM, Mofenson LM, Hughes MD, Seage GR 3rd, Ciupak GL, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team.

Pediatrics. 2002 May;109(5):E74-4.

PMID:
11986480
4.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
5.

Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.

Pediatrics. 2005 Feb;115(2):e173-82. Epub 2005 Jan 3.

PMID:
15629958
6.

Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment.

Lee GM, Gortmaker SL, McIntosh K, Hughes MD, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219C Team.

Pediatrics. 2006 Feb;117(2):273-83.

PMID:
16452344
7.

Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.

Nachman SA, Lindsey JC, Pelton S, Mofenson L, McIntosh K, Wiznia A, Stanley K, Yogev R.

Arch Pediatr Adolesc Med. 2002 May;156(5):497-503.

PMID:
11980557
8.

Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.

Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, Hughes M, Abrams EJ, Flynn PM, Borkowsky W, Yogev R; PACTG Protocol 345 Team.

Pediatr Infect Dis J. 2005 Sep;24(9):793-800.

PMID:
16148846
9.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
10.

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.

Buchacz K, Cervia JS, Lindsey JC, Hughes MD, Seage GR 3rd, Dankner WM, Oleske JM, Moye J.

Pediatrics. 2001 Oct;108(4):E72.

PMID:
11581480
11.

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG; Pediatric Spectrum of HIV Disease Consortium.

Pediatrics. 2007 Apr;119(4):e900-6. Epub 2007 Mar 12.

PMID:
17353299
12.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042
13.

Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.

Jeremy RJ, Kim S, Nozyce M, Nachman S, McIntosh K, Pelton SI, Yogev R, Wiznia A, Johnson GM, Krogstad P, Stanley K; Pediatric AIDS Clinical Trials Group (PACTG) 338 & 377 Study Teams.

Pediatrics. 2005 Feb;115(2):380-7.

PMID:
15687448
14.

Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia.

Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, Vun MC, Ford N, Nouhin J, Nerrienet E.

Pediatrics. 2007 Nov;120(5):e1134-40. Epub 2007 Oct 22.

PMID:
17954553
15.

Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children.

Abadi J, Sprecher E, Rosenberg MG, Dobroszycki J, Sansary J, Fennelly G, Wiznia A.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):298-303.

PMID:
16540930
16.

Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).

Kapogiannis BG, Soe MM, Nesheim SR, Sullivan KM, Abrams E, Farley J, Palumbo P, Koenig LJ, Bulterys M.

Pediatrics. 2008 May;121(5):e1229-39. doi: 10.1542/peds.2007-0871.

PMID:
18450865
17.

Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.

Clin Infect Dis. 2008 Jan 15;46(2):305-12. doi: 10.1086/524752.

PMID:
18171267
18.
19.

Early language development in children exposed to or infected with human immunodeficiency virus.

Coplan J, Contello KA, Cunningham CK, Weiner LB, Dye TD, Roberge L, Wojtowycz MA, Kirkwood K.

Pediatrics. 1998 Jul;102(1):e8.

PMID:
9651460
20.

Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.

Kline MW, Rugina S, Ilie M, Matusa RF, Schweitzer AM, Calles NR, Schwarzwald HL.

Pediatrics. 2007 May;119(5):e1116-20. Epub 2007 Apr 9.

PMID:
17420261

Supplemental Content

Support Center